Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
We monitor throughout treatment
The peptide is not found naturally in the human body
TennCare has covered GLP-1 precursors and their counterparts since they became FDA approved in 2005 as add-on therapy for diabetes management, and cardiovascular disease mid-year 2024, consistent with federal requirements and TennCare Medical Necessity Rules
Note that routine amylase/lipase monitoring is not recommended in asymptomatic patients
Book your appointment today to start your transformation
While the core patent in India expires in March 2026, the US patent was granted a Patent Term Extension (PTE) that pushes exclusivity to December 2031
US$ 26.10
US$ 29.93
US$ 21.54
